This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
JH-II-127 is an orally inhibitor of leucine-rich repeat kinase 2 (LRRK2). It inhibits WT LRRK2, G2019S LRRK2 and A2016T LRRK2 (IC50s = 6.6, 2.2, and 47.7 nM, respectively),